Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 120, Suppl. 1, 2012
Issue release date: August 2012
Section title: UK Renal Registry 14th Annual Report
Nephron Clin Pract 2012;120(suppl 1):c145–c174
(DOI:10.1159/000342851)

Chapter 8 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2010: National and Centre-Specific Analyses

Webb L.a · Gilg J.a · Wilkie M.b
a UK Renal Registry, Bristol, UK; b Sheffield Teaching Hospitals, Sheffield, UK
email Corresponding Author

Julie Gilg

UK Renal Registry, Southmead Hospital, Southmead Road,

Bristol, BS10 5NB, UK

Email: renalregistry@renalregistry.nhs.uk

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure. Aim: To determine the extent to which the guidelines for anaemia management are met in the UK. Methods: Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010. Results: In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb ≥10.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5–12.3 g/dl. Of HD patients 84.6% had Hb ≥10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6–12.5 g/dl). Of UK PD patients, 87.2% had Hb ≥10.0 g/dl. The median ferritin in HD patients in EWNI was 444 µg/L (IQR 299–635) and 96% of HD patients had a ferritin ≥100 µg/L. The median ferritin in PD patients was 264 µg/L (IQR 148–426) with 86% of PD patients having a ferritin ≥100 µg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,020 vs. 6,202 IU/week). Conclusions: Of prevalent HD patients, 52.7% had Hb ≥10 and ≤12 g/dl. Of prevalent PD patients, 54.3% had Hb 10.5–12.5 g/dl.

© 2012 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of UK Renal Registry 14th Annual Report

Published online: September 01, 2012
Issue release date: August 2012

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.